Navidea Biopharmaceuticals will receive payments totaling $1 million for fulfilling two commercial milestones for its Lymphoseek radiopharmaceutical.
The company will collect a $500,000 milestone payment from Cardinal Health, based on the sale of the 100,000th patient dose of the agent since its launch. It will receive the same amount from Dutch pharmaceutical company Norgine, thanks to approval of the Lymphoseek 50-microgram kit by the European Medicines Agency's Committee for Medicinal Products for Human Use, Navidea said.
